Servier Deal Termination Fails To Dent MacroGenics’ Flotetuzumab Optimism

The French firm has handed back rights to MacroGenics’ lead DART candidate flotetuzumab. Undaunted, MacroGenics is forging ahead with clinical development including in combination use, while the market awaits a filing and license deal for its lead product margetuximab.

Steps
• Source: Shutterstock

Servier SA is ending its license and collaboration agreement with MacroGenics Inc.for the investigational anticancer flotetuzumab (CD3 x CD123 DART bispecific) and other earlier-stage DART programs.

The agreement, inked in September 2012, will terminate on 15 January 2020 (unless agreed to sooner) upon which MacroGenics will...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip